Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternatives and developing countries.

J B Milstien1, N Dellepiane

  • 1Vaccine Supply and Quality Unit, Global Programme for Vaccines and Immunization, World Health Organization, Geneva, Switzerland.

Developments in Biological Standardization
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines on stability evaluation of vaccines.

Biologicals : journal of the International Association of Biological Standardization·2009
Same author

Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?

Vaccine·2008
Same author

Strengthening immunization in a West African country: Mali.

Education for health (Abingdon, England)·2007
Same author

Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test.

Vaccine·2001
Same author

Mass psychogenic illness following tetanus-diphtheria toxoid vaccination in Jordan.

Bulletin of the World Health Organization·2001
Same author

Ensuring vaccine safety in immunization programmes--a WHO perspective.

Vaccine·2001

This article examines how alternative testing methods can be used to ensure vaccine production consistency, particularly in developing nations. It highlights the requirements for successfully implementing these methods, including robust regulatory frameworks, quality management systems, and specialized staff expertise.

Area of Science:

  • Vaccine development and alternative testing strategies within public health
  • Regulatory science and quality assurance in developing countries

Background:

No prior work has fully resolved the challenges of implementing non-animal vaccine testing methods in resource-limited settings. That uncertainty drove the need to evaluate how these procedures fit into existing production workflows. It was already known that consistency testing remains a pillar of biological product safety. Prior research has shown that shifting away from traditional animal-based assays requires significant institutional support. This gap motivated a closer look at the specific requirements for adopting modern analytical techniques. Such transitions depend heavily on the maturity of local oversight bodies. Experts have long debated how to balance innovation with the strict safety standards required for biologicals. The current landscape necessitates a clear understanding of the infrastructure needed to support these sophisticated diagnostic tools.

Purpose Of The Study:

The aim of this review is to identify the factors influencing the adoption of alternative testing methods for vaccine production. This work addresses the specific challenges faced by developing countries in modernizing their quality control processes. The authors seek to clarify the institutional requirements for transitioning away from traditional animal-based assays. This motivation stems from the need to ensure consistent and safe biological products globally. The study explores how regulatory bodies can better support the implementation of these new techniques. It examines the interplay between laboratory quality systems and national oversight capabilities. The researchers intend to provide a framework for understanding the prerequisites for technical innovation in this sector. This effort highlights the necessity of aligning scientific advancement with robust administrative and regulatory structures.

Keywords:
regulatory infrastructurequality assurancebiological productsvaccine safety

Frequently Asked Questions

The authors propose that these methods confirm production consistency by providing standardized, reproducible data. Unlike traditional animal-based assays, these approaches rely on specific analytical protocols that ensure each vaccine batch meets predefined quality benchmarks, thereby reducing variability in the manufacturing process.

The researchers identify laboratory quality systems as a primary requirement. These frameworks ensure that all testing procedures are documented, standardized, and performed under controlled conditions, which is necessary for the reliable validation of any new analytical method in a regulatory context.

The authors state that strong national regulatory infrastructure is necessary because it provides the legal and technical oversight required to validate new methods. Without such a framework, local authorities cannot effectively monitor or approve the transition from traditional to alternative testing protocols.

Related Experiment Videos

Main Methods:

Review Approach involved a systematic synthesis of the requirements for modernizing biological product evaluation. The authors examined the intersection of laboratory standards and regulatory oversight. This analysis focused on the practical barriers faced by emerging economies. The team evaluated the necessity of quality management systems in supporting new diagnostic procedures. They assessed the role of specialized human capital in maintaining high-level safety standards. The review synthesized evidence regarding the validation of non-traditional analytical assays. This strategy prioritized the identification of institutional gaps that hinder the adoption of new technologies. The authors utilized a comparative framework to contrast traditional methods with emerging alternatives.

Main Results:

Key Findings From the Literature indicate that alternative methods are effective for confirming the consistency of vaccine batches. The authors report that the successful use of these tools depends on four primary factors. First, a deep understanding of both the test and the specific product is required. Second, a strong national regulatory infrastructure must be in place to oversee the process. Third, laboratories must operate under strict quality management principles. Fourth, the ability to validate the chosen method is essential for regulatory approval. The review finds that these requirements are often challenging for developing nations to meet simultaneously. The authors highlight that technical laboratory skills must be paired with regulatory expertise. The findings suggest that these elements are interconnected and cannot be addressed in isolation.

Conclusions:

Synthesis and Implications suggest that alternative methods provide a viable pathway for confirming the uniformity of vaccine batches. The authors emphasize that success relies on the presence of a robust national regulatory framework. Implementing these protocols requires laboratories to adhere strictly to established quality management standards. The researchers propose that authorities must cultivate deep expertise in both epidemiology and quality assurance processes. This review indicates that technical proficiency alone is insufficient without strong administrative oversight. The findings imply that international cooperation could help bridge the gap in regulatory capacity. The authors conclude that the adoption of these tests is a multifaceted process involving both scientific and policy dimensions. Future efforts should focus on building the necessary human capital to sustain these advanced testing environments.

The researchers note that epidemiology data plays a role in informing the broader context of vaccine safety. While laboratory results provide the technical evidence, epidemiological expertise allows regulators to interpret these findings in relation to population health outcomes and long-term product performance.

The authors measure the success of this transition by the ability to validate the alternative method. This involves demonstrating that the new test is as reliable and accurate as the established procedure it replaces, ensuring that safety standards are maintained throughout the change.

The researchers propose that national regulatory authorities must possess specialized expertise in quality assurance. This skill set is required to oversee the validation process and ensure that laboratories maintain the high standards necessary for consistent and safe vaccine production.